AVDL Avadel Pharma: Forward P/S Multiple

Avadel Pharmaceuticals (AVDL) aims to reshape the narcolepsy therapy market by introducing the innovative Lumryz to displace outdated treatment methods. The forward price-to-sales ratio confirms this trajectory, with the parameter reaching 8.50. Niche dominance is secured by a unique nightly dosing regimen, while rapid sales growth drives the drug's current commercial success in the US.

AVDL (avadel.com) Price-to-Projected Revenue Ratio history from 08/13/2023 to 02/28/2026

Avadel Pharmaceuticals - analytical breakdowns and key metrics (AVDL)

- market price and analyst price targets:

Price Chart avadel.com|AVDL - Average Forecast Price

- company stock capitalization data:

Market Capitalization Avadel Pharmaceuticals|AVDL - Enterprise Value

- issuer book value statistics:

Accounting Value per Share Avadel Pharmaceuticals|AVDL - Company Book Value|Market Capitalization to Book Value Ratio avadel.com|AVDL - Company Total Assets

- issuer credit burden and liquidity indicators:

- net income and valuation multiples indicators:

AVDL - Profit After Tax|Projected Future Earnings Avadel Pharmaceuticals|AVDL - Company Value to Net Income|Forward P/E Multiple Avadel Corp|AVDL - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avadel Pharmaceuticals PLC|AVDL - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Avadel Pharmaceuticals|AVDL - Net earnings per share for the last 12 months|Quarterly EPS earnings growth avadel.com|AVDL - Earnings growth in current year|Earnings growth forecast for next year Avadel Pharmaceuticals

- sales revenue and business income indicators:

AVDL - Company Sales|Projected Sales Volume avadel.com|AVDL - Price to Sales|Forward Price-to-Revenue Multiple Avadel Pharmaceuticals

Initial company analysis:AVDL (Avadel Pharma)

The expansion of the drug Lumryz within the neuropsychiatry market directly impacts the market valuation of Avadel Pharmaceuticals (AVDL). The forward P/S ratio measures the business value relative to expected sales, revealing the company's hidden vulnerabilities to a potential takeover. This metric is calculated by dividing the current share price by the projected revenue for the following year. A decline in this ratio makes the asset attractive to a strategic buyer, yet it may signal internal issues.

Who Avadel Pharmaceuticals competes with

Price-to-Projected Revenue Ratio alkermes.com ALKS|atai Life Sciences Corp (ATAI) - Market Cap to Future Revenue Ratio|GH Research Group - Forward P/S Multiple|Mind Medicine (MNMD) - Forward Price-to-Revenue Multiple|COMPASS Corp (CMPS) - Price-to-Projected Revenue Ratio|LBRX (LB Pharma) - Price-to-Projected Revenue Ratio|DRUG (Bright Minds Corp) - Forward P/S Multiple|Market Cap to Projected Revenue VNDA (Vanda Pharmaceuticals Inc)|Forward P/S Multiple CYBN|ANRO - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio NRx Pharmaceuticals NRXP|Forward P/S Multiple Cingulate Inc. CING|SILO - Price-to-Projected Revenue Ratio|Forward Price to Sales CPHI (China Pharma Holdings, Inc.)|CMND: Forward P/S Multiple|Psyence Biomedical Ltd. - Forward Price to Sales|SPRC (SciSparc Ltd.) - Forward P/S Multiple|SEEL (Seelos Therapeutics, Inc.) - Price to Expected Revenue Ratio|Forward P/S Multiple VRPX|KRTX (Karuna) - Forward Price to Sales